Summary Flavone acetic acid (FAA) is a compound with proven activity against various transplantable colon cancers in mice. In this study it was evaluated against primary colon tumours, chemically induced by methylazoxymethanol in outbred CF1 mice. FAA was given i.v. at doses of 70 or 100 or 150mgkg-1 every 7 days for 6 weeks. Only 4 out of 60 FAA treated mice died of toxicity. FAA reduced tumour number and tumour burden compared to control mice (P <0.05 at least), with no apparent dose-response relationship. Antitumour activity of FAA was comparable to that of 5-fluorouracil (5-FU) used as standard. Moreover, FAA was more effective that 5-FU against large tumours. FAA levels in plasma and different tissues (including colonic neoplastic lesions) after a single i.v. dose of 150mgkg-1 were investigated. Tumour FAA levels appear insufficient to be responsible for the antitumour activity based only on a direct FAA cytotoxic effect.
The results confirm clinical interest in FAA and suggest that mechanisms other than direct cytotoxicity may be involved in its activity.
Flavone acetic acid (FAA, NSC 347512, LM 975) has been recently identified as a potential new antitumour drug. It was selected largely on its activity against mouse colon adenocarcinoma 38, which responds weakly to available anticancer drugs (Plowman et al., 1986; O'Dwyer et al., 1987) . Successively Corbett et al. (1986) (Pratesi & Deschner, 1984) , has been recently described.
In the present study we evaluated the activity of FAA on MAM induced colon tumours and the drug distribution in tumour bearing mice.
Materials and methods

Animals
Outbred female CF1 mice, from Charles River Laboratories, USA, were used. They were received when 6-7 weeks old and maintained on chow and water ad libitum, in a controlled environment throughout the study.
Tumour induction
The experimental model has been described in detail elsewhere (Pratesi & Deschner, 1984 aration from Roche, Italy) diluted in sterile water was used as standard compound. Drugs were administered i.v. once a week for 6 weeks, in a volume of 10 ml kg-1 body weight (except for the dose of 150mg kg-1 FAA which was given in 15mlkg-1). Drug treatment started 23 weeks after the first MAM injection since at this time all mice were assumed to have tumours in the colonic mucosa. Some tumour-bearing animals, with intestinal obstruction, resulting in emaciation were excluded from the experimental groups. One week after the last drug treatment, all animals were killed by cervical dislocation. The organs were removed and placed in 10% neutral buffered formalin. Each large intestine was opened longitudinally and macroscopic tumours were counted (tumour number=TN). Mice without visible tumours were considered as TN 0. The volume of each tumour was calculated from caliper measurements as the product of the three dimensions, in mm3. The total tumour burden (TTB) was the sum of the single tumour volumes for each mouse. Average values (+s.e.) of TN and TTB for each group were calculated and the ratio of the value in treated (T) over control mice (C) x 100 was estimated (T/C %). Few mice died during the experiment and were not included in these calculations.
Pharmacokinetic studies CF 1 female mice, 30 weeks after the first MAM injection, were given an i.v. dose of 150mgkg-' FAA. Animals were killed 30, 60, 120min after treatment. At each time, plasma and tissues (liver, kidney, spleen, tumour and colon, after excision of in situ tumours) were collected separately from 4 animals. All samples were frozen immediately at -200 until analysis.
FAA was quantified by a modification of the HPLC method of Double et al. (1986) . Briefly, 100p1 plasma were added to 0.5mlH20, 200,u1 5% TCA and lOOpl flavone 8-propionic acetic acid as internal standard (kindly provided by Dr Nardi, Recordati, Italy). FAA was extracted with chloroform:isopropanol (1:1) and then mixed at room temperature for 1 h.
The precipitate and aqueous phase were sedimented by centrifugation for 15 min at 3000 rpm. The organic layer was then removed and dried under vacuum. The samples were resuspended in 200-400l1 methanol. Tissues were homogenized in water (liver 1:10 and other tissues 1:2) and 1 ml of the liver homogenate or the whole specimen for the others was processed as for plasma. Extracts were injected into a Waters Model 6000 A HPLC equipped with UV detector, set at 254nm. Separation was performed using an Table I ). The X-square test was used to compare the number of mice bearing <5 and >5 or more tumours in treated and in control groups (Table II) .
Results
FAA significantly reduced TN and TTB at all three doses tested (Table I ). In the range of doses used, no clear doseresponse relationship was observed, TN and TTB values not being statistically different after 70, 100 or 150mgkg-1. At the doses administered, FAA did not cause severe toxicity, only 4 out of 60 mice treated wtih the three doses died before the end of the experiment, and weight loss was not observed.
5-FU at its maximum tolerated dose of 52mg kg-1 (Pratesi et al., 1987) achieved 55% T/C for TN and 54% T/C for TTB (P<0.01 and P<0.05, respectively). Tumour inhibition was comparable to that attained by FAA. Table II shows, for each experimental group, the distribution of mice based on the number of tumours (less than or at least five) found at the end of the experiment. Both FAA and 5-FU treatments significantly reduced the number of tumours.
The distribution of tumours based on their volume is reported in Table III. In the control group or in 5-FU treated mice, 6 and 10% of tumours were > lOOmm3 respectively, whereas in FAA treated mice they were only 1-3% of the total number. The low frequency of large tumours in each FAA treated group makes a statistical comparison with the control group difficult. However when tumours larger than 100 mm3 in FAA treated mice were pooled together regardless the dose (5 tumours out of 260) a statistically significant difference (P<0.05 by X-square test) was achieved vs. control mice (10 out of 171) and vs. 5-FU treated mice (9 out of 94). 
Discussion
In the present study FAA reduced the number and burden of primary colonic tumours induced by MAM in mice. In previous in vivo studies evaluating the toxicity of FAA, the maximum cumulative tolerated dose was around 600mg kg-1 for a treatment period up to 20 days (Corbett et al., 1986) . In this study, a higher total dose could be given to mice in a longer period: in fact FAA doses up to 900mg kg-(150mg kg-1 for 6 times, weekly) were very well tolerated by all animals.
In previous studies, the FAA doses that showed significant antitumour activity were very close to the toxic ones (Corbett et al., 1986) . In contrast, in the experimental model we used, the antitumour effects of 70, 100 and 150mg kg-1 repeated doses were similar. Previous studies, however, employed s.c. transplanted tumours, whereas we investigated FAA activity in chemically induced tumours which grow in the colonic mucosa. We wonder whether the high susceptibility of MAM-induced tumours even to doses much lower than the toxic ones, might depend on their localization. The pharmacokinetic outline obtained however, does not indicate a preferential drug distribution in the colon tumours, where the FAA concentration was similar to or lower than that in other, normal tissues. Moreover in vitro studies on colon carcinoma cell lines showed growth inhibition at FAA concentrations greater than 400 Mg ml-1 for at least 24 hours Capolongo et al., 1987) and the FAA levels achieved in these primary tumours of mice after a dose of 150mg kg-1 appear to be too low to explain the observed tumour inhibition based only on a direct FAA cytotoxic effect. This reasoning is even more convincing when it is considered that doses of 70 and 100mgkg-1 were also effective against these tumours and presumably resulted in even lower FAA tumour concentrations.
Since the antitumour effects of FAA may be mediated by natural killer (NK) lymphocytes (Wiltrout, 1987; Ching & Baguley, 1987) and very high NK activity has been described in the murine gastrointestinal tract (Tagliabue et al., 1981) , these reasons could explain the effects achieved by FAA against primary colon tumours. A site-dependent sensitivity of tumours to FAA effects has already been reported by Double et al. (1987) and Giavazzi et al. (1988) . In the former paper, the murine colon MAC 15 tumour responded to FAA when growing s.c. and not when cells were injected i.v. or i.p. In the latter study, a human colon tumour xenograft, virtually insensitive when growing s.c., was extremely sensitive to FAA when growing in the liver after intrasplenic injection. No definitive explanations for these discrepancies have been reported by either authors.
In the present study, a lower number of large tumours was found in FAA treated mice than in untreated control mice. Even though this observation should be supported by more detailed studies, FAA seems more effective against large than against small neoplastic lesions. This is unusual for an anticancer agent, but could be in keeping with the recent proposed hypothesis that FAA acts much the same way as tumour necrosis factor (TNF) (Smith et al., 1987) and, like TNF, may be more effective on more advanced tumours (Manda et al., 1987) .
In conclusion, our study provides evidence that FAA is certainly effective against primary murine colon tumours, confirming the results against murine transplantable tumours. Moreover, mechanisms of action other than a direct cytotoxicity seem to be involved in its activity on murine models. Until now, however, no responses have yet been seen in early clinical investigation and this observation might reflect some fundamental difference between the way FAA actos in man and mouse. A better knowledge on mechanism of action of FAA might be needed as a basis for appropriate clinical investigations.
